和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 06-17 16:08:37

11.220

+1.100

+10.87%

最高11.270	最低10.150	成交量778.30万
今开10.170	昨收10.120	日振幅11.07%
总市值97.39亿	流通市值97.39亿	总股本8.68亿
成交额8,527万	换手率0.90%	流通股本8.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":11.22,"timestamp":1781683717003,"preClose":10.12,"halted":0,"volume":7783000,"delay":0,"changeRate":0.1086956521739132,"floatShares":868000000,"shares":868000000,"eps":0.8620216759268692,"marketStatus":"未开盘","change":1.1,"latestTime":"06-17 16:08:37","open":10.17,"high":11.27,"low":10.15,"amount":85267966,"amplitude":0.110672,"askPrice":11.22,"askSize":2000,"bidPrice":11.17,"bidSize":110000,"shortable":3,"etf":0,"ttmEps":0.862013839366179,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781746200000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":10.12,"openAndCloseTimeList":[[1781659800000,1781668800000],[1781672400000,1781683200000]],"volumeRatio":1.737044145819045,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2643223425","title":"和铂医药-B(02142)诉安进专利侵权胜诉获赔约2020.37万美元 最高可追偿三倍赔偿金","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223425","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223425?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:32","pubTimestamp":1781483572,"startTime":"0","endTime":"0","summary":"经过2026年6月8日开始的陪审团庭审后，陪审团认定：安进侵犯了Grosveld专利，该侵权行为属于故意侵权， Grosveld专利有效，及 Harbour Antibodies有权获得约2020.37万美元的损害赔偿——即公司请求的全额赔偿。故意侵权的认定使Harbour Antibodies有权请求法院提高损害赔偿金额，可能包括最高三倍的损害赔偿。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","IE00BJT1NW94.SGD","BK1574","LU2112291526.USD","LU0122379950.USD","BK4566","IE00BFTCPJ56.SGD","LU1983299246.USD","LU1023059063.AUD","LU2468319806.SGD","BK4599","LU2242652126.USD","BK4581","SG9999001440.SGD","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","LU1571399168.USD","BK4533","LU2089984988.USD","IE0002141913.USD","LU0109394709.USD","02142","IE00BJJMRZ35.SGD","AMGN","IE0009355771.USD","LU0289739699.SGD","BK4534","LU2242646821.SGD","IE00B4R5TH58.HKD","BK1161","BK1583","LU0868494617.USD","LU1057294990.SGD","LU1061106388.HKD","IE00B2B36J28.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191935413","title":"和铂医药-B：若全额判罚惩罚性赔偿，赔偿总额或增至约6060万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191935413","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191935413?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:03","pubTimestamp":1781481793,"startTime":"0","endTime":"0","summary":"和铂医药-B公告指出，若法院支持并全额判罚惩罚性赔偿，此案最终裁决的总赔偿金额可能攀升至约6060万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197751140","title":"和铂医药旗下Harbour Antibodies获判赔偿2020万美元 与庭审诉求全额一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1197751140","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197751140?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:03","pubTimestamp":1781481793,"startTime":"0","endTime":"0","summary":"和铂医药-B宣布，其子公司Harbour Antibodies在相关诉讼中被裁定有权获得2020万美元的损害赔偿，这一金额与公司在庭审中提出的全额索赔请求完全相符。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105174","title":"港股异动 | 超长效抗TSLP抗体II期临床完成首批给药 和铂医药-B(02142)、科伦博泰生物(06990)盘中均涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105174","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642105174?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:45","pubTimestamp":1781070342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B、科伦博泰生物今日逆市走高，截至发稿，和铂医药涨3.46%，报9.86港元；科伦博泰生物涨3.82%，报402.2港元。消息面上，6月9日，科伦博泰宣布，其合作伙伴Windward Bio主导的一项II期临床研究已完成首批患者给药。据悉，SKB378/WIN378最初由科伦博泰与和铂医药共同开发，双方平分全球权益。若后续临床试验顺利推进，SKB378/WIN378有望成为首款获批上市的超长效抗TSLP抗体，用于哮喘和COPD治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","LU0196878994.USD","BK1161","BK1574","02142","06990","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642746717","title":"和铂医药-B(02142)：全人源超长效靶向TSLP抗体HBM9378/WIN378治疗COPD的II期 SIRIUS研究已完成首批患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2642746717","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642746717?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:15","pubTimestamp":1781007333,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)发布公告，公司的合作伙伴Windward Bio AG(Windward \nBio)已在HBM9378/WIN378(亦称SKB378，一款全人源超长效靶向胸腺基质淋巴细胞生成素(TSLP)抗体)治疗慢性阻塞性肺疾病(COPD)的II期 \nSIRIUS研究中完成首批患者给药。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104190712","title":"和铂医药-B更新5月股份变动月报表，股本净增662,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1104190712","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104190712?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:47","pubTimestamp":1780584425,"startTime":"0","endTime":"0","summary":"2026年6月4日，和铂医药控股有限公司发布截至2026年5月31日的股份变动月报。公告显示，公司注册股本维持在20,000,000,000股，每股面值0.000025美元，注册股本总额500,000美元，与上月保持一致。报告期内，公司已发行股份由上月底的872,842,722股减少至867,607,722股，库存股份由25,937,000股增加至31,834,000股。截至月末，公司已发行及库存股份合计899,441,722股，较上月底净增662,000股。购回与库存情况方面，当月累计购回股份5,897,000股，其中406,000股拟注销但截至月末尚未实际注销，其余购回股份转为库存股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640549132","title":"港股异动 | 和铂医药-B(02142)午后涨超5% 公司近期公布首款AI候选药物LET003优异临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640549132","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640549132?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:16","pubTimestamp":1780553770,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B午后涨超5%，截至发稿，涨5.01%，报10.9港元，成交额6125.33万港元。消息面上，和铂医药此前公布其首款利用Hu-mAtrIx人工智能平台开发的下一代靶向ACVR2A/2B单克隆抗体药物LET003的临床前研究数据。结果显示，LET003具有优于多个竞品分子的药代动力学特征；与司美格鲁肽联合用药时，可显著增强减脂效果并有效保护瘦体重。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AIPO","CHAT","VXUS","BK1574","AGIX","BK1583","02142","BK4588","ARTY","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01919","00199","02050","06990","09926","02565","06681","09869","06603","08547","02418","02259","06110","01211","00152","00004","09866","02172","01516","02598","00087","00909","02506","00107","00981","02142","06699","00384","02609","00165","06613","00177","03888","01672","02291","02685","00117","00008","01473","06955","03986","09626","09993","02155","02587","00081","01477","02714","09880","01592"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174178093","title":"和铂医药-B：5月21日回购20万股，总涉资约238.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174178093","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174178093?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:01","pubTimestamp":1779361312,"startTime":"0","endTime":"0","summary":"2026年5月21日，和铂医药-B发布翌日披露公告显示，公司当日在香港联交所场内回购普通股20万股，涉及金额约238.46万港元。此次回购股份占公司截至2026年5月20日现有已发行股本的约0.023%，每股购回价介乎11.70港元至12.19港元。同日，公司根据2020年11月23日获股东批准的首次公开发售后股份奖励计划，向相关激励对象发行46,000股普通股，约占公司现有已发行股本的0.0053%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B：5月21日回购20万股，总涉资约238.46万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637872380","title":"和铂医药-B(02142)5月21日斥资238.46万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637872380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637872380?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:59","pubTimestamp":1779361187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月21日该公司斥资238.46万港元回购20万股，回购价格为每股11.70-12.19港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142845709","title":"和铂医药-B5月20日回购30万股，耗资约356.76万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142845709","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142845709?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:26","pubTimestamp":1779276405,"startTime":"0","endTime":"0","summary":"和铂医药-B于2026年5月20日发布公告，披露当日通过香港联交所场内回购公司股份并实施新股发行，涉及公司回购股份及已发行股本变动事宜。公告日期为2026年5月20日。该部分股份拟持作库藏股。公司表示，此次回购依据2025年6月11日获股东批准的回购授权进行，授权可回购股份总数为82,834,612股，截至目前公司已累计回购13,297,000股，占回购授权通过日已发行股本的1.605%。本次交易完成后，公司已发行股份总数为867,677,722股，同时库藏股数增至31,634,000股，合计899,311,722股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B5月20日回购30万股，耗资约356.76万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168743368","title":"和铂医药-B：5月19日回购50万股，涉资约615.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168743368","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168743368?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:51","pubTimestamp":1779191503,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年5月19日发布公告，披露在香港联交所场内回购普通股50万股，占本次事件前已发行股本约0.0576%，每股回购价介乎12.06港元至12.54港元，合计约615.45万港元。上述股份将被列为公司库藏股。本次回购与发行后，公司已发行股本为867,961,722股，库藏股数量为31,334,000股，总股本达899,295,722股。截至目前，公司已于香港联交所或其他证券交易所累计回购股份12,997,000股，占上述授权通过当日已发行股本约1.57%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B：5月19日回购50万股，涉资约615.45万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885555","title":"和铂医药-B(02142)5月19日斥资615.45万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885555","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636885555?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:50","pubTimestamp":1779191457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月19日，该公司斥资615.45万港元回购50万股股份，每股回购价和12.06-12.54港元。于2026年5月19日，该公司根据于2020年11月23日采纳及获公司股东批准的首次公开发售后股份奖励计划而发行2.2万股普通股以满足股份奖励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU1960683339.HKD","IE00B031HY20.USD","LU0348827113.USD","LU1719994722.HKD","06978","LU0072913022.USD","LU0326950275.SGD","LU2097828631.EUR","09926","CHAT","06185","BK1583","ARTY","LU1880383366.USD","LU0572944931.SGD","02616","LU1226288170.HKD","LU0856984785.SGD","LU0140636845.USD","AGIX","LU0561508036.HKD","09995","159992","LU1303224171.USD","01177","01801","AIPO","LU0067412154.USD","01877","LU1993786604.SGD","SG9999002562.SGD","02269","LU0456827905.SGD","LU0456846285.SGD","BK1161","LU0348767384.USD","LU1226287792.SGD","01093","BK1589","LU0417516738.SGD","02142","LU1152091168.USD","LU0634319403.HKD","IE00BPRC5H50.USD","BK1588","LU0315179316.USD","LU0516422952.EUR","06160","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1199468449","title":"和铂医药-B回购100万股并发行2.5万股新股，总涉资约1,251.17万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199468449","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199468449?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:46","pubTimestamp":1779097581,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年5月18日公告最新翌日披露报表，披露公司当日于香港联交所场内回购合计100万股股份，约占公司现有已发行股本0.115%。本次回购每股价格介乎港币12.18元至12.79元，合计支付约1,251.17万港元。回购的股份将被列作库存股。公司确认，本次股份回购及发行已获董事会正式授权，并遵守香港联交所证券上市规则及适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B回购100万股并发行2.5万股新股，总涉资约1,251.17万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636218330","title":"和铂医药-B(02142)5月18日斥资1251.17万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636218330","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636218330?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:42","pubTimestamp":1779097326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月18日该公司斥资1251.17万港元回购100万股，回购价格为每股12.18-12.79港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"497fd758b38c276bd0bec58e92fb66d5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02623","01021","03858","BK1171","01333","00363","02675","HK0001040143.USD","02411","01300","02655","02729","00650","00826","02575","06090","03317","03881","08299","02726","01907","02706","00400","BK1100","00290","02526","BK1155","LU0307460666.USD","02652","09696","06682","02889","00305","02685","06651","01384","06938","02228","02142","06636","LU0314109678.HKD","02670","01396","VXUS","01378","02659","02650","06051","LU0287142896.SGD","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","159992","LU0516423174.USD","06160","IE00B0JY6N72.USD","LU0456827905.SGD","LU1993786604.SGD","LU1152091754.HKD","02269","02616","IE00BZ08YS42.EUR","SG9999002562.SGD","BK1141","LU2399975544.HKD","LU0326950275.SGD","01093","IE00B543WZ88.USD","LU0588546209.SGD","LU2097828557.USD","IE00BZ08YT58.USD","09926","02142","LU0039217434.USD","01177","IE00B5MMRT66.SGD","LU2097828631.EUR","LU0359202008.SGD","LU0979878070.USD","LU0516422952.EUR","LU0348827113.USD","LU1969619763.USD","LU0417516738.SGD","BK1574","01877","09995","LU0561508036.HKD","06185","IE00BZ08YR35.GBP","LU1688375341.USD","LU1242518857.USD","09688","BK1588","601066","LU1242518931.SGD","LU1152091168.USD","LU1226287875.USD","LU1303224171.USD","LU2097828474.EUR","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636017186","title":"和铂医药-B(02142)公布首款AI开发下一代靶向ACVR2A/2B抗体LET003临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2636017186","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636017186?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:45","pubTimestamp":1779065119,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和铂医药-B 发布公告，公布其首款利用Hu-mAtrIx人工智能平台开发的下一代靶向ACVR2A/2B单克隆抗体药物LET003的临床前研究数据。据悉，LET003是一款潜在同类最佳的下一代单克隆抗体，靶向激活素受体ACVR2A/2B。LET003是首款依托HumAtrIx人工智能平台研发的ACVR2A/2B双靶点阻断抗体，具有优于多款竞品的药代动力学特性；在临床前动物模型中，其与GLP-1类药物联用也展现出优异的减脂与保肌增效作用。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","CHAT","BK1583","BK1574","BK1161","02142","AGIX","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012116","title":"和铂医药-B(02142)公布首款候选药物用于肥胖症治疗的下一代靶向ACVR2A/2B抗体LET003的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012116","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636012116?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:12","pubTimestamp":1779063123,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司董事会欣然宣布其首款利用Hu-mAtrIx人工智能平台开发的下一代靶向ACVR2A/2B单克隆抗体药物LET003的临床前研究数据。以上数据表明，在司美格鲁肽基础上联合LET003，可显著增强减脂效果，并有效缓解司美格鲁肽单药治疗可能导致的瘦体重流失。这些数据进一步证实，LET003联合司美格鲁肽不仅能够更有效地降低体脂比例，还能显著改善瘦体重比例，实现更优的身体成分调控。这表明LET003在促进瘦体重方面优于该竞品分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)公布首款候选药物用于肥胖症治疗的下一代靶向ACVR2A/2B抗体LET003的临床前数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.131},{"period":"1month","weight":-0.0973},{"period":"3month","weight":-0.0556},{"period":"6month","weight":-0.1589},{"period":"1year","weight":0.4459},{"period":"ytd","weight":-0.0773}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0531},{"period":"3month","weight":-0.0466},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0138},{"period":"ytd","weight":-0.0514}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.061755},{"month":7,"riseRate":0.4,"avgChangeRate":0.030357},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}